Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2019-09-11
Target enrollment:
Participant gender:
Summary
Phase II trial to evaluate trametinib in patients with locally advanced non-squamous,
non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with
progressive disease on at least one prior line of therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
American Cancer Society, Inc. Novartis Pharmaceuticals